The Hindu Business Line : Ranbaxy to sell anti-fungal drug in Australia

New Delhi, March 6 Ranbaxy Laboratories Ltd said on Friday it has received approval from Australia’s drug regulator to sell generic terbinafine tablets. Terbinafine is an anti-fungal drug used to treat skin infections.

Ranbaxy Australia, the wholly owned subsidiary of the company, has received an approval from the Therapeutic Goods Administration (TGA) for the registration of Sebifin Terbinafine tablets in Australia, a statement from the country’s largest drug-maker said.

The approval was based on the assessment by the TGA that the Ranbaxy formulation of terbinafine is bioequivalent to Lamisil tablets of Novartis Pharmaceuticals Australia, it added.

With the approval of this tablet, Ranbaxy now has a total number of 26 molecules approved for marketing in Australia, the statement said. The approved molecules cover a wide range of therapeutic areas including anti-hypertensive, anti-infective, anti-convulsants and anti-depressants, it added.

Shares of Ranbaxy Laboratories closed the day at Rs 141.30, down 2.15 per cent on the BSE.

Related Stories:
Ranbaxy gets USFDA nod for BP drug
USFDA action against Ranbaxy based on false drug stability data

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Essar Oil plans refinery shutdown for 18 days

JK Tyres rolls out tubeless tyres for after-market

Dunlop reopens Sahagunj plant

CLB decision vindicates our stand, says Maytas Infra

Award for Cookie Man head

Vishwakarma Award presented

Domestic probe against worker: Labour Court order quashed

Mahindra extends micro hybrid system to more vehicles

Stand alone and then b(l)end

Dalmia Cement scouting for land to set up new units

Coal India awarded two blocks in Mozambique

Ranbaxy to sell anti-fungal drug in Australia

Essar Group bets big on offshore services biz

Tata Steel sales up 47% in Feb